🔍

Link Pharma Chem Ltd (524748)

📊 BSE: 524748 🏢 Commodity Chemicals 📢 Latest filing: 13 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Link Pharma's revenue was ₹8.8 Cr (+12.3% year on year, +33.1% on the previous quarter), and net profit ₹0.3 Cr (-20.4% year on year); the operating margin was 5.2%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹8.8	+12.3%	+33.1%
Operating profit	₹0.5	-28.7%	from loss
Net profit	₹0.3	-20.4%	from loss
EPS (₹)	0.72	-20.0%	from loss
Operating margin	5.2%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

GST Demand Cut by 88% to Rs 16.30 Lakh by Vadodara Appellate Authority

🟢 POSITIVE ⭐ 4/10

LEGAL 📅 13 Oct 2026, 05:40 PM

Link Pharma Chem has received an order from the GST Appellate Authority, Tribunal Vadodara, for FY 2021-22. The appellate authority significantly reduced the final GST demand from Rs 1.33 crore to Rs 16.30 lakh, and the penalty was slashed from Rs 13.29 lakh to Rs 2.06 lakh. The case originated from discrepancies between GSTR-1 and GSTR-3B as well as excess ITC claims. The company noted there is no material impact on operations and plans to appeal the remaining liability further.

GST demand reduced from Rs 1,32,94,322 to Rs 16,29,852 for FY 2021-22
Penalty reduced from Rs 13,29,433 to Rs 2,05,605
Order received on October 12, 2026 from GST Appellate Authority, Tribunal Vadodara
Issues related to tax mismatches in GSTR1 vs GSTR3B and excess ITC claims not reflected in GSTR-2A
Company intends to file an appeal against the remaining demand with the appropriate authority

💡 Track subsequent legal updates to see if the residual demand of Rs 16.30 lakh plus penalty is contested successfully in the next appeal.

Link Pharma Chem Re-Appoints Rishikesh Thakur as Managing Director for 3 Years

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 20 Aug 2026, 08:15 PM

Link Pharma Chem Limited has announced the re-appointment of Mr. Rishikesh Thakur as Managing Director for a term of three years, effective September 24, 2026. The re-appointment was approved by shareholders at the Annual General Meeting held on August 20, 2026. Mr. Thakur brings over 15 years of industry experience and has previously led operations, R&D, and business development for the company. He is the son of Chairman & Whole-time Director Mr. Satish G. Thakur.

Re-appointed Mr. Rishikesh Thakur as Managing Director for a 3-year term
Tenure takes effect from September 24, 2026
Shareholder approval secured at the AGM held on August 20, 2026
Mr. Thakur has over 15 years of experience in the chemical manufacturing industry

💡 Track operational execution and subsequent quarterly earnings to evaluate margin recovery, as the company generated Rs 28 Cr in TTM revenue with modest operating margins of 4.4%.

Link Pharma Chem Re-Appoints Rishikesh Thakur as MD for 3-Year Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 20 Aug 2026, 08:13 PM

Link Pharma Chem Ltd has re-appointed Mr. Rishikesh Thakur as Managing Director for a 3-year term, effective September 24, 2026. The re-appointment was approved by shareholders at the Annual General Meeting held on August 20, 2026. Mr. Thakur, who holds a B. Eng. in Polymer and has over 15 years of industry experience, is the son of Chairman & Whole-time Director Satish G. Thakur. The move provides leadership continuity for the microcap chemical manufacturer, which reported TTM revenue of ₹28 Cr.

Re-appointment of Mr. Rishikesh Thakur as Managing Director for a period of 3 years
Term effective from September 24, 2026 following approval at AGM held on August 20, 2026
Appointee possesses over 15 years of extensive chemical industry and operations experience
Related-party disclosure notes appointee is the son of Chairman Mr. Satish G. Thakur

💡 Track subsequent quarterly financial performances and margin improvement initiatives under continued management leadership.

Link Pharma Chem Shareholders Approve All 6 AGM Resolutions with 99.74% Majority

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 20 Aug 2026, 07:43 PM

Link Pharma Chem Limited has submitted the voting results and Scrutinizer's Report for its 41st Annual General Meeting held on August 20, 2026. All six resolutions were approved by shareholders with a 99.74% majority (26,11,759 votes in favour vs. 6,939 against). Key approvals include the adoption of FY26 audited financial statements, the re-appointment of Satish G. Thakur as Chairman & Whole-time Director, and the re-appointment of Rishikesh Thakur as Managing Director. A total of 47 shareholders attended the meeting via video conferencing.

All 6 resolutions passed with 99.74% votes in favour (26,11,759 votes) and 0.26% against (6,939 votes)
Re-appointment of Satish G. Thakur as Chairman & Whole-time Director approved via Special Resolution
Re-appointment of Rishikesh Thakur as Managing Director approved via Special Resolution
A total of 47 shareholders (3 promoters and 44 public) attended the AGM out of 6,004 total shareholders as on the record date (August 13, 2026)

💡 Track the company's upcoming Q2 FY27 operational and financial performance to evaluate business turnaround and margin improvement.

Link Pharma Chem Q1 Results: PAT at ₹0.32 Cr, Revenue Grows 12% YoY to ₹8.77 Cr

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 05 Aug 2026, 02:35 PM

Link Pharma Chem reported a recovery in Q1 FY27, turning profitable with a PAT of ₹0.32 Cr compared to a loss of ₹0.41 Cr in the previous quarter (Mar 2026). Revenue from operations grew 12.2% YoY to ₹8.77 Cr and 33% sequentially. While the turnaround is positive, operating margins remain thin, and nearly 46% of the Profit Before Tax (₹0.18 Cr out of ₹0.39 Cr) was derived from fair value gains on financial assets rather than core operations. The company remains a micro-cap with a market capitalization of only ₹11 Cr.

Revenue from operations increased to ₹8.77 Cr from ₹7.81 Cr in the same quarter last year.
Net Profit stood at ₹0.32 Cr, recovering from a loss of ₹0.41 Cr in the March 2026 quarter.
Fair value gains on financial assets contributed ₹0.18 Cr to the total income of ₹9.12 Cr.
Cost of materials consumed rose to ₹3.78 Cr compared to ₹2.70 Cr in the year-ago period.
Earnings Per Share (EPS) improved to ₹0.72 from a negative ₹0.92 in the preceding quarter.

💡 Investors should monitor if the company can sustain a quarterly revenue run-rate above ₹9 Cr to maintain profitability, as the current margins are highly sensitive to raw material price fluctuations.

Link Pharma Chem Q1 Results: Revenue Grows 12% YoY to ₹8.77 Cr, Returns to Profitability

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 05 Aug 2026, 02:19 PM

Link Pharma Chem reported a recovery in Q1 FY27 (ending June 2026) with revenue of ₹8.77 Cr, up 12.2% from ₹7.81 Cr in the same quarter last year. The company posted a Net Profit of ₹0.32 Cr, a significant turnaround from the ₹0.41 Cr loss recorded in the preceding quarter (March 2026). However, profitability remains fragile as Other Income of ₹0.35 Cr accounted for nearly 90% of the Profit Before Tax (₹0.39 Cr). With a micro-cap valuation of ₹11 Cr and debt of ₹7 Cr, the company's financial stability remains closely tied to maintaining these quarterly revenue levels.

Revenue from operations increased to ₹8.77 Cr from ₹7.81 Cr in the year-ago period.
Net Profit reached ₹0.32 Cr compared to a loss of ₹0.41 Cr in the previous quarter.
Other Income of ₹0.35 Cr included a fair value gain of ₹0.18 Cr on financial assets.
Cost of materials consumed stood at ₹3.78 Cr, approximately 43% of total revenue.
Finance costs rose to ₹0.14 Cr, up from ₹0.10 Cr in the corresponding quarter last year.

💡 Watch for the sustainability of operating margins in upcoming quarters to see if the company can generate profits from core operations without relying on fair value gains in 'Other Income'.

Link Pharma Chem to Hold 41st AGM on August 20, 2026; Dispatches Annual Report Links

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Jul 2026, 06:31 PM

Link Pharma Chem Ltd has scheduled its 41st Annual General Meeting (AGM) for August 20, 2026, to be conducted via video conferencing. The company has dispatched physical letters containing the web link for the FY 2025-26 Annual Report to shareholders who have not registered their email addresses. Key administrative dates include a cut-off of August 13, 2026, for voting eligibility and a remote e-voting period from August 17 to August 19, 2026. This follows a fiscal year where the company reported a TTM revenue of Rs 27 crore against a small market capitalization of Rs 11 crore.

41st Annual General Meeting scheduled for August 20, 2026, at 11:30 AM.
Cut-off date for e-voting and AGM participation set for August 13, 2026.
Remote e-voting window open from August 17 (9:00 AM) to August 19, 2026 (5:00 PM).
Letters dispatched to shareholders as of the cut-off date of July 24, 2026.

💡 Investors should access the Annual Report via the provided link to evaluate the company's operational recovery, given the TTM PAT is currently near zero.

Link Pharma Chem to Consider Q1 FY27 Results on August 5, 2026

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 28 Jul 2026, 03:21 PM

Link Pharma Chem has scheduled a board meeting for August 5, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position with a market capitalization of only Rs 11 crore and a high P/E of 140. In the preceding quarter (March 2026), the company reported a net loss of Rs 0.41 crore on revenue of Rs 6.59 crore. Investors will be looking for a recovery in margins, which stood at a low 5.2% on a TTM basis.

Board meeting scheduled for August 5, 2026, to approve Q1 FY27 results
Trading window has been closed since July 1, 2026, as per SEBI regulations
Company reported a net loss of Rs 0.41 crore in the previous quarter ended March 2026
TTM revenue stands at Rs 27 crore against a market cap of Rs 11 crore
Promoter holding remained stable at 52.4% as of June 2026

💡 Monitor the August 5 results to see if the company can reverse the net loss trend seen in the March 2026 quarter and improve its low ROCE of 3.5%.

41st AGM Scheduled for August 20, 2026; Book Closure from August 14

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jul 2026, 06:38 PM

Link Pharma Chem Ltd has announced its 41st Annual General Meeting (AGM) will be held on August 20, 2026, via video conferencing. The company has fixed August 13, 2026, as the cut-off date to determine shareholder eligibility for remote e-voting. To facilitate this, the register of members and share transfer books will remain closed from August 14 to August 20, 2026. This is a standard procedural filing required under SEBI regulations and the Companies Act.

41st Annual General Meeting scheduled for August 20, 2026, at 11:30 A.M.
Book closure period set from August 14, 2026, to August 20, 2026 (both days inclusive).
Cut-off date for remote e-voting eligibility is fixed as August 13, 2026.
The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

💡 Investors should review the upcoming AGM notice for details on the company's strategy to address its FY25 net loss of Rs 1.03 Cr and low ROCE of 3.5%.

Link Pharma Chem FY26 Annual Report: Revenue at ₹27.43 Cr, Returns to Marginal Profitability

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 27 Jul 2026, 04:14 PM

Link Pharma Chem has submitted its FY2025-26 Annual Report, highlighting a recovery from losses to a marginal net profit of ₹0.0769 Cr (₹7.69 Lacs). Revenue grew 7.8% year-on-year to ₹27.43 Cr. The company has scheduled its 41st AGM for August 20, 2026, to seek approval for the re-appointment of its Chairman and Managing Director. Despite the turnaround, the net profit margin remains extremely thin at 0.28%, and proposed management remuneration significantly exceeds the annual profit.

Revenue from operations increased to ₹27.43 Cr in FY26 from ₹25.43 Cr in FY25.
Net Profit turned positive at ₹0.0769 Cr compared to a loss of ₹1.03 Cr in the previous fiscal.
Proposed monthly remuneration for Chairman Satish Thakur is ₹4.00 Lacs (₹48 Lacs annually).
Proposed monthly remuneration for MD Rishikesh Thakur is ₹3.00 Lacs (₹36 Lacs annually).
Return on Capital Employed (ROCE) improved to 4.44% from -5.26% in the prior year.

💡 Investors should monitor the AGM on August 20, 2026, specifically regarding the sustainability of the turnaround and the high management remuneration relative to the company's small profit base.

41st AGM on Aug 20: Re-appointment of MD and Chairman with Rs 7 Lakh Combined Monthly Salary

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 27 Jul 2026, 03:40 PM

Link Pharma Chem has scheduled its 41st Annual General Meeting (AGM) for August 20, 2026. Key agenda items include the re-appointment of Mr. Satish Thakur as Chairman & Whole-time Director and Mr. Rishikesh Thakur as Managing Director, both for three-year terms. The proposed monthly salaries are Rs 4.00 Lacs and Rs 3.00 Lacs respectively, totaling Rs 84 Lakhs annually. This combined remuneration is significant, representing approximately 3.1% of the company's TTM revenue of Rs 27 Cr, especially given the company's marginal profitability (TTM PAT near zero).

41st AGM scheduled for August 20, 2026, at 11:30 AM via Video Conferencing.
Proposed re-appointment of Chairman Mr. Satish Thakur at a salary of Rs 4.00 Lacs per month.
Proposed re-appointment of MD Mr. Rishikesh Thakur at a salary of Rs 3.00 Lacs per month.
Combined annual executive remuneration of Rs 84 Lakhs against a TTM revenue of Rs 27 Cr.
Appointment of Secretarial Auditor for a 4-year tenure from FY 2026-27 to FY 2029-30.

💡 Investors should monitor the AGM voting results, specifically the approval of executive remuneration in the context of the company's low ROCE (3.5%) and recent quarterly losses.

View All 524748 Announcements on Live Market Tracking →